Old Web
English
Sign In
Acemap
>
authorDetail
>
J. Brahmer
J. Brahmer
Medicine
Erlotinib
Cancer research
Oncology
Internal medicine
5
Papers
35
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Immunomodulation of Checkpoints Resets Immune System in NSCLC
2014
J. Powers
J. Brahmer
Show All
Source
Cite
Save
Citations (0)
Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC)
2008
Journal of Clinical Oncology
Alan Sandler
David H. Johnson
J. Brahmer
Joan H. Schiller
M. Ostland
Robert M. Gray
S. Tran
Isaiah W. Dimery
Show All
Source
Cite
Save
Citations (29)
Validation of proteomic classifier for clinical benefit from erlotinib as first line treatment for advanced non-small cell lung cancer (ECOG 3503)
2007
Journal of Clinical Oncology
B. J. Solomon
H. Röder
R Robert
Fumiko Taguchi
J. Brahmer
S. H. Joan
M.W. Duncan
F. R. Hirsch
P. A. Bunn
David P. Carbone
Show All
Source
Cite
Save
Citations (0)
Final results of ECOG 3503: A pilot study to determine if downstream markers of EGFR linked signaling pathways predict response to erlotinib (OSI-774) in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
2007
Journal of Clinical Oncology
Jill M. Kolesar
J. Brahmer
Sigui Li
P. P. Guaglianone
Jyoti D. Patel
Michael Keppen
Manuel Hidalgo
David P. Carbone
Jill M. Siegfried
Joan H. Schiller
Show All
Source
Cite
Save
Citations (6)
1